DNMT1 and breast carcinoma: To further validate the methylated regulation of CMTM7 promoter region, the DNA methyltransferases (DNMT) inhibitor AZA was used for treating breast cancer cells at the concentrations of 1.0, 1.5, 2.0, and 2.5 μM.